The emergence of 'omics for the management of colorectal cancer

Current Opinion in Oncology

Volumn 23, Issue 4, 2011, Pages 410-414

  Midgley, Rachel S ^a   Church, David ^a   Kerr, David J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

biomarkers; chemotherapy; colorectal; predictive; prognosis

Indexed keywords

TUMOR MARKER;

CLINICAL PRACTICE; COLORECTAL CANCER; GENE EXPRESSION; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PUBLISHING; REVIEW;

ANTINEOPLASTIC PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 79958859532     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328347ae49     Document Type: Review

References (30)

1. Gray R, Barnwell J, McConkey C, et al. QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group. Lancet 2007; 370:2020-2029.
2. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
3. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993; 104:57-64. (Pubitemid 23040006)
4. Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993; 104:1044-1048. (Pubitemid 23090756)
5. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995; 55:5217-5221.
6. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998; 16:427-433. (Pubitemid 28135583)
7. Lanza G, Matteuzzi M, Gafa R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79:390-439.
8. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-1206. (Pubitemid 32319494)
9. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102:1136-1141.
10. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331:213-221. (Pubitemid 24226678)
11. Diep CB, Thorstensen L, Meling GI, et al. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 2003; 21:820-829. (Pubitemid 46606441)
12. Cohn KH, Ornstein DL, Wang F, et al. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cancer 1997; 79:233-244. (Pubitemid 27029887)
13. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-5257. (Pubitemid 28521189)
14. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002; 360:1381-1391. (Pubitemid 35341303)
15. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91:1295-1303. (Pubitemid 29387571)
16. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-1206. (Pubitemid 32319494)
17. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23:609-618. (Pubitemid 46224239)
18. Van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452:564-570. (Pubitemid 351483370)
19. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447:433-440. (Pubitemid 46816750)
20. Brennan DJ, O'Connor DP, Rexhepaj E, et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 2010; 10:605-617.
21. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008; 452:553-563. (Pubitemid 351483369)
22. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536. (Pubitemid 34130608)
23. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564-1571. (Pubitemid 41079793)
24. Jiang Y, Casey G, Lavery IC, et al. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn 2008; 10:346-354. (Pubitemid 352019121)
25. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24:4685-4691. (Pubitemid 46630932)
26. Barrier A, Lemoine A, Boelle PY, et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005; 24:6155-6164. (Pubitemid 43080065)
27. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526-3535.
28. Salazar R, Roepman P, CapellaG, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29:17-24.
29. Salazar RM, Stork-Sloots J, Simon L, et al. The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint. J Clin Oncol 2010; 28:15s (suppl; abstr TPS199).
30. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study J Clin Oncol 2009; 27:15s (suppl; abstr 4000).